Skip to main content
Equibles
DNLI logo

DNLI · Denali Therapeutics Inc. · Metrics

Track DNLI — free

Use DNLI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DNLI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.26 +0.19 (+0.95%) Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$3.22B
Shares
160.29M
Volume · Nov 9 168.51K Avg daily vol (3M) 1.64M

DNLI metrics

69 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.07
Market cap
$3.22B

Price action

23 metrics
Price change (1W)
+6.0%
Price change (30D)
+3.2%
Price change (3M)
-19.2%
Price change (6M)
+2.3%
Price change (YTD)
+21.6%
Price change (1Y)
+39.3%
Trailing year
Price change (5Y)
-63.5%
52-week high
$27.21
52-week low
$14.41
Change from 52-week high
-26.2%
Change from 52-week low
+39.3%
Annualized volatility
55.6%
Annualized volatility (3M)
42.0%
Implied volatility (30D)
57.1%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.6
RSI (14D)
54.1
Price vs SMA 50
-0.4%
Price vs SMA 200
-5.6%
Avg volume (3M)
1.64M
Relative volume
1.0
Average dollar volume
$34.07M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
160.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
150.5×
reciprocal yield 0.7%
P / book
3.5
reciprocal yield 28.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-03

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$532.01M
Net income (TTM)
−$314.42M
Trailing 12 months
Diluted EPS (TTM)
$-1.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.88
EBITDA per diluted share (TTM)
$-2.81
Net income per diluted share (TTM)
$-1.74
Operating cash flow per diluted share (TTM)
$-2.39
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$2.18
Stock compensation per diluted share (TTM)
$0.50
Book value per share
$6.49

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$21.38M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-33.9%
Return on assets
-25.0%
Debt / equity
—
Current ratio
6.2
EBITDA (TTM)
−$519.16M
Free cash flow (TTM)
—
Quick ratio
5.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$516.20M
Latest balance sheet
Cash & equivalents
$102.87M
Total assets
$1.26B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$444.19M
Capital expenditures (TTM)
$5.80M
R&D (TTM)
$404.87M
SG&A (TTM)
—
Stock compensation (TTM)
$92.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
298
13F filer change QoQ
+25
Institutional ownership
98.2%
Conviction holders (share of 13F filers)
1.7%
Crowding (high-turnover and private-fund holders)
22.2%
Private-fund adviser ownership
21.8%
Active holders' share change QoQ
+5.9%
Holder tenure
16.0
Price vs estimated holder cost
+36.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
18.4%

Short interest

3 metrics
Short interest
9.7%
Latest settlement · 8.1 days to cover
Days to cover
8.1d
Short-squeeze score
70 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$435,303
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1714899 CUSIP 24823R105 13F (30d) 125 filings 107 filers Visit website Investor relations